CN103463090A - Preparation method of sitagliptin metformin hydrochloride compound preparation - Google Patents
Preparation method of sitagliptin metformin hydrochloride compound preparation Download PDFInfo
- Publication number
- CN103463090A CN103463090A CN201310412920XA CN201310412920A CN103463090A CN 103463090 A CN103463090 A CN 103463090A CN 201310412920X A CN201310412920X A CN 201310412920XA CN 201310412920 A CN201310412920 A CN 201310412920A CN 103463090 A CN103463090 A CN 103463090A
- Authority
- CN
- China
- Prior art keywords
- preparation
- weight
- sitagliptin
- metformin hydrochloride
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004034 sitagliptin Drugs 0.000 title claims abstract description 56
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 229960004329 metformin hydrochloride Drugs 0.000 title claims abstract description 34
- -1 sitagliptin metformin hydrochloride compound Chemical class 0.000 title claims abstract description 25
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims abstract description 38
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000000945 filler Substances 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 239000000314 lubricant Substances 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 4
- 239000007921 spray Substances 0.000 claims description 22
- 238000005469 granulation Methods 0.000 claims description 18
- 230000003179 granulation Effects 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000011230 binding agent Substances 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000443 hydrochloric acid Drugs 0.000 claims description 2
- 229960004115 sitagliptin phosphate Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- RTZRUVMEWWPNRR-UHFFFAOYSA-N tert-butyl n-(3-iodo-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C2NC=C(I)C2=C1 RTZRUVMEWWPNRR-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000002156 mixing Methods 0.000 abstract description 6
- 239000000853 adhesive Substances 0.000 abstract 2
- 230000001070 adhesive effect Effects 0.000 abstract 2
- 238000005453 pelletization Methods 0.000 abstract 2
- 238000005507 spraying Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 25
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- 229960003105 metformin Drugs 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 238000005550 wet granulation Methods 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000013019 agitation Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000859 incretin Substances 0.000 description 3
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 102100036968 Dipeptidyl peptidase 8 Human genes 0.000 description 1
- 101710087011 Dipeptidyl peptidase 8 Proteins 0.000 description 1
- 102100036969 Dipeptidyl peptidase 9 Human genes 0.000 description 1
- 101710087005 Dipeptidyl peptidase 9 Proteins 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a preparation method of a sitagliptin metformin hydrochloride compound preparation. The preparation method comprises the following steps of (1) preparing a pelletization solution by using sitagliptin and an adhesive; (2) mixing metformin hydrochloride, a filler and a disintegrating agent; (3) spraying the pelletization solution in the step (1) onto the surface of the mixture in the step (2) for pelleting; (4) drying and granulating; and (5) adding a lubricating agent, and uniformly mixing, wherein the sum of the using percentages of the materials is 100 percentage by weight, and the adhesive can be mixed with the metformin hydrochloride, the filler and the disintegrating agent together in the step two instead of being added in the step (1). The preparation method can be used for preparing the sitagliptin metformin hydrochloride compound preparation with relatively good sitagliptin content uniformity, especially tablets.
Description
Technical field
The present invention relates to a kind of preparation method of sitagliptin metformin hydrochloride compound preparation.
Background technology
Sitagliptin is a kind of DPP-4(dipeptidyl peptidase-IV) inhibitor, it plays a role by the activation that delays the incretin in the type 2 diabetes mellitus patient body.Sitagliptin increases and extends action effect and time in the body of this hormone by the bulk concentration that increases this hormone.Incretin is the part of the endogenous system of glucose homeostasis physiological regulation, and it comprises glucagon-like-peptide-1 (GLP-1) and dependence on the glucose Xing Cu island element polypeptide (GIP), can be discharged by small intestinal in whole day, but increase to some extent in level after the meal.When blood sugar concentration is normal or raise, GLP-1 and GIP increase the synthetic of insulin and discharge by beta Cell of islet by signal pathway (comprising cyclic adenosine monophosphate) in cell.GLP-1 also can reduce alpha Cell of islet secretion glucagon, thereby reduces liver synthesizing glucose.Sitagliptin increases the release of insulin by the level that increases and extend active incretin, and reduces the level of glucose in the circulation of blood glucose dependency.Sitagliptin shows the selectivity retardance effect of DPP-4 and can not block DPP-8(dipeptidyl peptidase-VIII close to the external concentration level of therapeutic dose) or DPP-9(dipeptidyl peptidase-IX).
Metformin is a kind of biguanides, can improve type 2 diabetes mellitus patient's glycemic control, reduces basic blood sugar level and level of postprandial blood sugar.Metformin can reduce synthetic to glucose of liver, reduces small intestinal and increases insulin sensitivity to the absorption of glucose and by picked-up and the utilization that improves the periphery glucose.Metformin can not cause hypoglycemia in type 2 diabetes mellitus patient and healthy population under normal circumstances, can not cause hyperinsulinemia yet.During using Or Metformin In Treating, the secretion of insulin is unaffected, but the fasting insulin level and in the daytime insulin level really can decrease.
In July, 2012, state food and drug administration has ratified to be used for the treatment of the new oral tablet of type 2 diabetes mellitus
this medicine formally went on the market in Chinese market on January 24th, 2013.
be the complex of first orally-taken blood sugar reducing medicine DPP-4 inhibitor, it contains two kinds can provide lasting ingredient-sitagliptin and the metformin of effectively controlling blood glucose.
for the type 2 diabetes mellitus patient provides the excessively strong treatment selection of output of the large defect of direct attack disease three-beta Cell of islet insulin deficit, insulin resistant and hepatic glycogen.
Chinese patent CN101365432B discloses the pharmaceutical composition of the combination of dipeptidyl peptidase-4 inhibitors and metformin, has described tablet formulation of DPP-4 inhibitor and metformin combination and preparation method thereof.This pharmaceutical composition comprises by weight 3～20% DPP4-inhibitor or its pharmaceutically acceptable salt, 25～94% Metformin, 0.1～10% lubricant, 0～35% binding agent.Preparation method is, after DPP-4 inhibitor and metformin hydrochloride are put into to high speed shear wet granulator or fluid bed and mixed, first to add purified water to be granulated, and after drying, adds the aqueous solution of binding agent further to granulate, drying again.Then the dried particles made is ground, the fine grained that grinding is obtained is mixed homogeneously and is carried out tabletting, coating with filler, lubricant etc.Also can for example roll by pharmaceutical composition by direct pressing or dry granulation, be prepared.
Summary of the invention
In above-mentioned patent, the shared ratio great disparity of DPP-4 inhibitor and metformin hydrochloride-DPP-4 inhibitor: 3～20%, preferably 5～18%; Metformin hydrochloride: the particle size range of 25～94%, preferably 65～77%, and two kinds of crude drug may be inconsistent, so this technical scheme exists the DPP-4 inhibitor to mix inhomogeneous probability with metformin hydrochloride.
For solving this technical problem, the invention provides a kind of preparation method of sitagliptin metformin hydrochloride compound preparation, said method comprising the steps of:
1) by 1～18 % by weight, preferably the sitagliptin of 2～15 % by weight is dissolved in purified water, adds 0.5～8 % by weight, and preferably the binding agent of 1～3 % by weight is made granulation solution;
2) by 20～95 % by weight, the preferably metformin hydrochloride of 50～80 % by weight and 10～40 % by weight, the preferably filler of 10～20 % by weight, 1～10 % by weight, preferably the disintegrating agent of 1～3 % by weight is mixed;
3) granulated in the granulation spray solution of step 1 to the mixture surface of step 2;
4) drying, granulate;
5) add the mix lubricant of 0.5～3 % by weight even;
In said method, the usage ratio summation of each material is 100 % by weight.
In said method, can in step 1), not add binding agent, and in step 2 yet) in described binding agent is mixed together with metformin hydrochloride, filler, disintegrating agent.
The granule that method of the present invention makes can be directly granule, or granule is made to tablet or capsule etc.In one embodiment, the inventive method gained granule is made to tablet.
When being made into tablet, the granule of getting aforementioned preparation carries out tabletting.Preferably, can carry out coating after tabletting.
Use method of the present invention can make the better sitagliptin metformin hydrochloride of sitagliptin uniformity of dosage units compound preparation, especially tablet.
The specific embodiment
The invention provides a kind of preparation method of sitagliptin metformin hydrochloride compound preparation, said method comprising the steps of:
1) by 1～18 % by weight, preferably the sitagliptin of 2～15 % by weight is dissolved in purified water, adds 0.5～8 % by weight, and preferably the binding agent of 1～3 % by weight is made granulation solution;
2) by 20～95 % by weight, the preferably metformin hydrochloride of 50～80 % by weight and 10～40 % by weight, the preferably filler of 10～20 % by weight, 1～10 % by weight, preferably the disintegrating agent of 1～3 % by weight is mixed;
3) granulated in the granulation spray solution of step 1 to the mixture surface of step 2;
4) drying, granulate;
5) add the mix lubricant of 0.5～3 % by weight even;
In said method, the usage ratio summation of each material is 100 % by weight.
Described sitagliptin comprises sitagliptin and pharmaceutically acceptable salt thereof, such as sitagliptin phosphate, sitagliptin phosphate monohydrate, hydrochloric acid sitagliptin or sulphuric acid sitagliptin etc.
In step 1),
Described binding agent is the conventional any binding agent used in this area, for example polyvinylpyrrolidone (PVP), hydroxypropyl emthylcellulose (HPMC), hydroxypropyl cellulose (HPC), sodium carboxymethyl cellulose (CMC-Na) or its mixture.
Step 1) can be under magnetic agitation beaker or rustless steel container in carry out.
In step 2) in,
Described filler is the conventional any filler used in this area except lactose, for example microcrystalline Cellulose, starch, mannitol, sucrose or dextrin, preferably microcrystalline cellulose.
Described disintegrating agent is the conventional any disintegrating agent used in this area, for example cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose or pregelatinized Starch.
Step 2) mixing can be carried out in pelletizer, such as wet-mixed fast granulating machine, multifunctional top spray fluid bed etc., and while wherein being mixed in the wet-mixed fast granulating machine, rotating speed of agitator is 1000rpm, the shredder bar rotating speed is 800rpm.
In step 3),
Described sprinkling can be used for example spray gun to realize.The atomizing pressure of spray gun is 0.5～2.0bar.
In step 4),
Drying is carried out in fluid bed, and when dry, temperature of charge is 30～50 ℃, and preferably 40 ℃, the air intake flow is 50～120m
3/ h, preferably 70m
3/ h, being dried to pellet moisture is 1～3%.
Step 5) lubricant used is the conventional any lubricant used in this area, such as magnesium stearate, Pulvis Talci, micropowder silica gel, fumaroyl sodium stearate etc.
In said method, can in step 1), not add binding agent, and in step 2 yet) in described binding agent is mixed together with metformin hydrochloride, filler, disintegrating agent.
Use method of the present invention can make the better sitagliptin metformin hydrochloride of sitagliptin uniformity of dosage units compound preparation, especially tablet.
Describe the present invention in detail referring to embodiment, should be understood that following embodiment is intended to explanation, is not construed as limiting the present invention.
Hereinafter listed the reagent and the medicine source that use in an embodiment:
Sitagliptin phosphate monohydrate: self-control (preparation method is referring to CN102516184A)
Metformin hydrochloride: Shandong Keyuan Pharmaceutical Co.,Ltd
Jie Nuoda: Mo Shadong pharmaceutical Co. Ltd
Microcrystalline Cellulose: German JRS company
Cross-linking sodium carboxymethyl cellulose: U.S. FMC Corp.
Magnesium stearate: Ahua Pharmaceutical Co., Ltd., Liaocheng, Shandong
Opadry, I Opadry II, HPMC (5cp): Shanghai Colorcon Coating Technology Co., Ltd
Polyvinylpyrrolidone: American I SP company
Low-substituted hydroxypropyl cellulose, fumaroyl sodium stearate: Anhui Shanhe Medical Accessary Material Co., Ltd.
Potassium dihydrogen phosphate: 1Guanghua Chemical Plant Co., Ltd., Guangdong
Acetonitrile: Sinence Company Inc
Methanol: Spain's Sa labor company limited
The preparation of embodiment 1. sitagliptin metformin hydrochloride Compound Tablets
(1) in beaker, 64.25g sitagliptin phosphate monohydrate is joined in the 600mL purified water, add 30g polyvinylpyrrolidone magnetic agitation to be prepared into the granulation solution of wet granulation;
(2) 500g metformin hydrochloride and 200g microcrystalline Cellulose, 10g cross-linking sodium carboxymethyl cellulose are put into to Mini-CG-2/10 wet-mixed fast granulating machine and mix, during mixing, rotating speed of agitator is 1000rpm, and the shredder bar rotating speed is 800rpm;
(3) use spray gun device that the granulation spray solution is carried out to wet granulation to the mixture surface of (2), the atomizing pressure of spray gun is 0.8bar;
(4) dry in fluid bed after granulation, granulate, when dry, temperature of charge is 40 ℃, the air intake flow is 70m
3/ h, being dried to pellet moisture is 1%;
(5) in the granule of (4), add the 5g magnesium stearate to mix, use C& C800 tablet machine tabletting, prepare 1000 altogether;
(6) use Opadry
the row coating, coating weightening finish 2%, obtain sitagliptin metformin hydrochloride Compound Tablet.
The preparation of embodiment 2. sitagliptin metformin hydrochloride Compound Tablets
(1) in rustless steel container, 64.25g sitagliptin phosphate monohydrate is joined in the 800mL purified water, add 10g hydroxypropyl emthylcellulose (5cp) magnetic agitation to be prepared into the granulation solution of wet granulation;
(2) 1000g metformin hydrochloride and 300g microcrystalline Cellulose, 20g cross-linking sodium carboxymethyl cellulose being put into to GPCG2 multifunctional top spray fluid bed mixes;
(3) use spray gun device that the granulation spray solution is carried out to wet granulation to the mixture surface of (2), the atomizing pressure of spray gun is 1.0bar;
(4) dry in fluid bed after granulation, granulate, when dry, temperature of charge is 35 ℃, the air intake flow is 100m
3/ h, being dried to pellet moisture is 1%;
(5) in the granule of (4), add the 10g micropowder silica gel to mix, use C& C800 tablet machine tabletting, prepare 1000 altogether;
(6) use Opadry
the row coating, coating weightening finish 3%, obtain sitagliptin metformin hydrochloride Compound Tablet.
The preparation of embodiment 3. sitagliptin metformin hydrochloride Compound Tablets
(1) in beaker, 124.06g sitagliptin phosphate monohydrate is joined in the 800mL purified water, add 20g polyvinylpyrrolidone magnetic agitation to be prepared into the granulation solution of wet granulation;
(2) the 1000g metformin hydrochloride is put into to the wet-mixed fast granulating machine with 200g microcrystalline Cellulose, 30g low-substituted hydroxypropyl cellulose and mix, during mixing, rotating speed of agitator is 1000rpm, and the shredder bar rotating speed is 800rpm;
(3) use spray gun device that the granulation spray solution is carried out to wet granulation to the mixture surface of (2), the atomizing pressure of spray gun is 1.2bar;
(4) dry after granulation, granulate, when dry, temperature of charge is 45 ℃, the air intake flow is 110m
3/ h, being dried to pellet moisture is 1%;
(5) in the granule of (4), add 15g fumaroyl sodium stearate to mix, use C& C800 tablet machine tabletting, prepare 1000 altogether;
(6) use the aqueous solution of 1%HPMC (5cp) to carry out coating, coating weightening finish 2%, obtain sitagliptin metformin hydrochloride Compound Tablet.
The preparation of embodiment 4. sitagliptin metformin hydrochloride Compound Tablets
(1) in beaker, 124.06g sitagliptin phosphate monohydrate is joined in the 800mL purified water, magnetic agitation is prepared into the granulation solution of wet granulation;
(2) the 1000g metformin hydrochloride is put into to the wet-mixed fast granulating machine with 200g microcrystalline Cellulose, 20g polyvinylpyrrolidone, 30g low-substituted hydroxypropyl cellulose and mix, during mixing, rotating speed of agitator is 1000rpm, and the shredder bar rotating speed is 800rpm;
(3) use spray gun device that the granulation spray solution is carried out to wet granulation to the mixture surface of (2), the atomizing pressure of spray gun is 1.2bar;
(4) dry after granulation, granulate, when dry, temperature of charge is 45 ℃, the air intake flow is 110m
3/ h, being dried to pellet moisture is 2%;
(5) in the granule of (4), add 15g fumaroyl sodium stearate to mix, use C& C800 tablet machine tabletting, prepare 1000 altogether;
(6) use the aqueous solution of 1%HPMC (5cp) to carry out coating, coating weightening finish 2%, obtain sitagliptin metformin hydrochloride Compound Tablet.
Embodiment 5. sitagliptin uniformity of dosage units detect
Use high performance liquid chromatography to detect the content of sitagliptin in preparation.The highly effective liquid phase chromatographic system used is Waters e2695-2489, mobile phase is 0.02mM potassium phosphate buffer (pH4.6)-acetonitrile-methanol (30:50:20), flow velocity is 1.0mL/min, the detection wavelength is 220nm, chromatographic column is Symmertry Waters C18 post (150 * 4.6mm, 5 μ m).1, tablet getting embodiment 1 is placed in the 100mL volumetric flask, add above-mentioned mobile phase to about 50mL, ultrasonic 3min, then add mobile phase and be diluted to scale, shakes up, filter, collect filtrate, precision measures in filtrate 5mL to 50mL volumetric flask, adds mobile phase and is diluted to scale, shake up, be mixed with containing the about sample solution a of 50 μ g/mL of sitagliptin.The tablet a slice of separately getting embodiment 4 is placed in the 100mL volumetric flask, add above-mentioned mobile phase to about 50mL, ultrasonic 3min, then add mobile phase and be diluted to scale, shakes up, filter, collect filtrate, precision measures in filtrate 5mL to 50mL volumetric flask, adds mobile phase and is diluted to scale, shake up, be mixed with containing the about sample solution b of 50 μ g/mL of sitagliptin.Get sitagliptin phosphate monohydrate reference substance 6.425mg, put in the 100mL volumetric flask, add mobile phase and dissolve and be diluted to scale, shake up, be mixed with the reference substance solution containing sitagliptin 50 μ g/mL.Get reference substance solution, each 25 μ L injection liquid chromatographies of sample solution, record chromatogram, calculate respectively the content of embodiment 1 and embodiment 2 every middle sitagliptins by external standard method.According to two appendix X E of Chinese Pharmacopoeia version in 2010, get the tablet of 10 embodiment 1 preparation, measure respectively every and take the sitagliptin relative amount X that labelled amount is 100, ask its meansigma methods
absolute value with the difference of standard deviation S and labelled amount and average
calculate the value of A+1.80S.Get again the tablet of 10 embodiment, 4 preparations, calculate the value of its A+1.80S according to identical method.
Get 10 of Jie Nuoda, measure respectively according to the method described above every and take the sitagliptin relative amount X that labelled amount is 100, ask its meansigma methods
absolute value with the difference of standard deviation S and labelled amount and average
calculate the value of A+1.80S.Tablet and the Jie Nuoda of embodiment 1 and embodiment 4 are compared, the results are shown in table 1.
Sitagliptin uniformity of dosage units contrast in table 1 Jie Nuoda and embodiment 1 tablet
By result, can be found out, the sitagliptin compound tablet made by embodiment 2 or embodiment 4, the A+1.80S value of its sitagliptin is significantly less than the A+1.80S value of Jie Nuoda, illustrates that the sitagliptin in the Compound Tablet that method of the present invention makes all has better uniformity of dosage units with respect to Jie Nuoda.
Claims (9)
1. the preparation method of a sitagliptin metformin hydrochloride compound preparation said method comprising the steps of:
1) by 1～18 % by weight, preferably the sitagliptin of 2～15 % by weight is dissolved in purified water, adds 0.5～8 % by weight, and preferably the binding agent of 1～3 % by weight is made granulation solution;
2) by 20～95 % by weight, the preferably metformin hydrochloride of 50～80 % by weight and 10～40 % by weight, the preferably filler of 10～20 % by weight, 1～10 % by weight, preferably the disintegrating agent of 1～3 % by weight is mixed;
3) granulated in the granulation spray solution of step 1 to the mixture surface of step 2;
4) drying, granulate;
5) add the mix lubricant of 0.5～3 % by weight even;
In said method, the usage ratio summation of each material is 100 % by weight.
2. preparation method according to claim 1, wherein sitagliptin is sitagliptin phosphate, sitagliptin phosphate monohydrate, hydrochloric acid sitagliptin or sulphuric acid sitagliptin.
3. preparation method according to claim 2, wherein binding agent is polyvinylpyrrolidone, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose or its mixture.
4. preparation method according to claim 3, wherein said filler is microcrystalline Cellulose, starch, dew alcohol, sucrose or dextrin, preferably microcrystalline cellulose.
5. preparation method according to claim 4, wherein said disintegrating agent is cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose or pregelatinized Starch.
6. preparation method according to claim 5, wherein said lubricant is magnesium stearate, Pulvis Talci, micropowder silica gel or fumaroyl sodium stearate.
7. preparation method according to claim 6, wherein step 2) be blended in pelletizer and carry out, described pelletizer is wet-mixed fast granulating machine or multifunctional top spray fluid bed.
8. preparation method according to claim 7, wherein said sprinkling is used spray gun to realize, and the atomizing pressure of spray gun is 0.5～2.0bar.
9. the preparation method of claim 1-7 any one does not wherein add binding agent in step 1), and in step 2) in described binding agent is mixed together with metformin hydrochloride, filler, disintegrating agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310412920XA CN103463090A (en) | 2013-09-11 | 2013-09-11 | Preparation method of sitagliptin metformin hydrochloride compound preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310412920XA CN103463090A (en) | 2013-09-11 | 2013-09-11 | Preparation method of sitagliptin metformin hydrochloride compound preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103463090A true CN103463090A (en) | 2013-12-25 |
Family
ID=49788285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310412920XA Pending CN103463090A (en) | 2013-09-11 | 2013-09-11 | Preparation method of sitagliptin metformin hydrochloride compound preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103463090A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104771377A (en) * | 2015-04-15 | 2015-07-15 | 海南华益泰康药业有限公司 | Preparation method of immediate release oral preparation containing sitagliptin or sitagliptin pharmaceutical salt |
| CN110215437A (en) * | 2019-07-18 | 2019-09-10 | 北京中惠药业有限公司 | A kind of metformin hydrochloride tablet and preparation method thereof |
| CN115245495A (en) * | 2022-09-21 | 2022-10-28 | 北京惠之衡生物科技有限公司 | A kind of sitagliptin and metformin tablet and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101365432A (en) * | 2005-12-16 | 2009-02-11 | 默克公司 | Pharmaceutical composition of dipeptidyl peptidase-4 inhibitor in combination with metformin |
| CN101932241A (en) * | 2008-02-05 | 2010-12-29 | 默沙东公司 | Combination pharmaceutical composition of metformin and dipeptidyl peptidase-IV inhibitor |
| CN101959406A (en) * | 2008-03-04 | 2011-01-26 | 默沙东公司 | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor |
| CN102740839A (en) * | 2009-11-13 | 2012-10-17 | 百时美施贵宝公司 | immediate release tablet |
-
2013
- 2013-09-11 CN CN201310412920XA patent/CN103463090A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101365432A (en) * | 2005-12-16 | 2009-02-11 | 默克公司 | Pharmaceutical composition of dipeptidyl peptidase-4 inhibitor in combination with metformin |
| CN101932241A (en) * | 2008-02-05 | 2010-12-29 | 默沙东公司 | Combination pharmaceutical composition of metformin and dipeptidyl peptidase-IV inhibitor |
| CN101959406A (en) * | 2008-03-04 | 2011-01-26 | 默沙东公司 | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor |
| CN102740839A (en) * | 2009-11-13 | 2012-10-17 | 百时美施贵宝公司 | immediate release tablet |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104771377A (en) * | 2015-04-15 | 2015-07-15 | 海南华益泰康药业有限公司 | Preparation method of immediate release oral preparation containing sitagliptin or sitagliptin pharmaceutical salt |
| CN104771377B (en) * | 2015-04-15 | 2017-06-09 | 海南华益泰康药业有限公司 | A kind of preparation method of the oral preparation of quick releasing containing sitagliptin or its pharmaceutical salts |
| CN110215437A (en) * | 2019-07-18 | 2019-09-10 | 北京中惠药业有限公司 | A kind of metformin hydrochloride tablet and preparation method thereof |
| CN110215437B (en) * | 2019-07-18 | 2021-10-08 | 北京中惠药业有限公司 | A kind of metformin hydrochloride tablet and preparation method thereof |
| CN115245495A (en) * | 2022-09-21 | 2022-10-28 | 北京惠之衡生物科技有限公司 | A kind of sitagliptin and metformin tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103655570B (en) | Sitagliptin and metformin compound slow release preparation and preparation method thereof | |
| KR101977785B1 (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof | |
| EP4025192B1 (en) | Process for producing a tablet comprising glp-1 peptides | |
| WO2014104671A1 (en) | Pharmaceutical composition with improved stability, containing temozolomide, and preparation method therefor | |
| WO2021238978A1 (en) | Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor | |
| KR20150138800A (en) | Solid composition of amino carboxylate salt | |
| CN102499923A (en) | Drug combination, as well as preparation method and application of same | |
| CN103463090A (en) | Preparation method of sitagliptin metformin hydrochloride compound preparation | |
| CN104721188A (en) | Stable composition containing Alogliptin benzoate | |
| JPH0813736B2 (en) | Method for preparing tablets or dragee compositions containing heat-, light-, and moisture-sensitive active ingredients having a monoclinic crystal structure | |
| CN104997744B (en) | A kind of high stability capecitabine tablet and preparation method thereof | |
| CN102755301B (en) | Glimepiride tablet and preparation method thereof | |
| CN104086490B (en) | A kind of glipizide compound and the pharmaceutical composition containing this compound and preparation method thereof | |
| CN114042051A (en) | Pharmaceutical composition containing sitagliptin and metformin and preparation method thereof | |
| CN103385863A (en) | Sodium azulene sulfonate sustained-release preparation | |
| CN103705515A (en) | Method for preparing pharmaceutical composition containing repaglinide and metformin hydrochloride | |
| CN103110601B (en) | Gliclazide gastric floating tablet and preparation method thereof | |
| KR102290295B1 (en) | Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate | |
| CN102218064B (en) | Pharmaceutical combination with repaglinide and metformin as active components and preparation method thereof | |
| CN108670958A (en) | A kind of preparation method of voglibose effervescent tablet | |
| JP2001213890A (en) | Trehalose particles | |
| JPH0710747A (en) | Solid preparation and its production | |
| CN105534929A (en) | Trelagliptin pharmaceutical composition | |
| CN105663131A (en) | Repaglinide and metformin hydrochloride tablet pharmaceutical composition and preparation method thereof | |
| CN104224783A (en) | Medicine composition containing repaglinide and metformin and preparation method of medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131225 |